Results 171 to 180 of about 27,938 (222)
Effect of preoperative β-blocker use on Analgesia-Nociception Index during laparoscopic cholecystectomy. [PDF]
J Clin Monit ComputBom JS, Lee S, Yoo YC, Kim J.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Opinion in Critical Care, 2001
Remifentanil is an opioid with a unique pharmacokinetic profile. Its metabolism by nonspecific esterases results in rapid and uniform clearance leading to highly predictable onset and offset of action. This review will describe the features that set remifentanil apart from other opioids and outline its potential usefulness in a critical care setting ...
J, Cohen, D, Royston
openaire +2 more sources
Remifentanil is an opioid with a unique pharmacokinetic profile. Its metabolism by nonspecific esterases results in rapid and uniform clearance leading to highly predictable onset and offset of action. This review will describe the features that set remifentanil apart from other opioids and outline its potential usefulness in a critical care setting ...
J, Cohen, D, Royston
openaire +2 more sources
Drugs, 1996
Remifentanil is a new selective mu opioid receptor agonist of higher potency than alfentanil, with pharmacological effects that essentially parallel those of alfentanil and other opioids in this class. Unlike other opioids, remifentanil is rapidly hydrolysed by nonspecific plasma and tissue esterases: this imparts brevity of action, precise and rapidly
S S, Patel, C M, Spencer
openaire +2 more sources
Remifentanil is a new selective mu opioid receptor agonist of higher potency than alfentanil, with pharmacological effects that essentially parallel those of alfentanil and other opioids in this class. Unlike other opioids, remifentanil is rapidly hydrolysed by nonspecific plasma and tissue esterases: this imparts brevity of action, precise and rapidly
S S, Patel, C M, Spencer
openaire +2 more sources
The pharmacokinetics of remifentanil
Journal of Clinical Anesthesia, 1996Opioids decrease the sympathetic and somatic responses to noxious stimulation and can be given in high doses without negative inotropic effects, even in patients with impaired cardiac function. With currently available opioids, precise titration of dose to effect is difficult, and high doses result in drug accumulation and prolonged respiratory ...
L G, Michelsen, C C, Hug
openaire +2 more sources
Acta Anaesthesiologica Scandinavica, 2008
Background and aim: Remifentanil is an ultra‐short‐acting opioid, increasingly used today in neuroanesthesia and neurointensive care. Its characteristics make remifentanil a potentially ideal agent, but previous data have cast a shadow on this opioid, supporting potentially toxic effects on the ischemic brain.
FODALE, Vincenzo +3 more
openaire +4 more sources
Background and aim: Remifentanil is an ultra‐short‐acting opioid, increasingly used today in neuroanesthesia and neurointensive care. Its characteristics make remifentanil a potentially ideal agent, but previous data have cast a shadow on this opioid, supporting potentially toxic effects on the ischemic brain.
FODALE, Vincenzo +3 more
openaire +4 more sources
Intensive and Critical Care Nursing, 2002
Remifentanil is a synthetic opioid receptor agonist that was introduced in 1997 for analgesia during general anaesthesia. However, it recently received a license for analgesia and sedation in ventilated intensive care patients and so is now of interest to those working in intensive care.
openaire +3 more sources
Remifentanil is a synthetic opioid receptor agonist that was introduced in 1997 for analgesia during general anaesthesia. However, it recently received a license for analgesia and sedation in ventilated intensive care patients and so is now of interest to those working in intensive care.
openaire +3 more sources
Pediatric Anesthesia, 2010
SummaryRemifentanil has gained the confidence of anesthesiologists and has given a real opportunity to change the way anesthesia is given. It can be considered the ideal opioid despite many obstacles to pediatric use: the condition of ‘off‐label’, the lack of wide randomized clinical trials, and the fear of adverse events because of its high potency ...
Maria, Sammartino +4 more
openaire +2 more sources
SummaryRemifentanil has gained the confidence of anesthesiologists and has given a real opportunity to change the way anesthesia is given. It can be considered the ideal opioid despite many obstacles to pediatric use: the condition of ‘off‐label’, the lack of wide randomized clinical trials, and the fear of adverse events because of its high potency ...
Maria, Sammartino +4 more
openaire +2 more sources
Current Opinion in Anaesthesiology, 2008
The present study summarizes the knowledge to date of the use of remifentanil in obstetric anaesthesia and analgesia.Modest labour analgesia, particularly for the first stage, can be achieved using a patient-controlled analgesia bolus of 40 microg with a 2-min lockout.
openaire +2 more sources
The present study summarizes the knowledge to date of the use of remifentanil in obstetric anaesthesia and analgesia.Modest labour analgesia, particularly for the first stage, can be achieved using a patient-controlled analgesia bolus of 40 microg with a 2-min lockout.
openaire +2 more sources
Current Opinion in Anaesthesiology, 2003
Remifentanil has now reached maturity, as reflected by the increasing number of clinical papers relating to its use. Its position among anaesthetic drugs is now better understood, and this review will attempt to place it in the context of current clinical practice.Propofol reduces the initial distribution of remifentanil, leading to higher ...
openaire +2 more sources
Remifentanil has now reached maturity, as reflected by the increasing number of clinical papers relating to its use. Its position among anaesthetic drugs is now better understood, and this review will attempt to place it in the context of current clinical practice.Propofol reduces the initial distribution of remifentanil, leading to higher ...
openaire +2 more sources